Last reviewed · How we verify
Fundação Altino Ventura — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Preservative free artificial tear | Preservative free artificial tear | marketed | Artificial tear / Ocular lubricant | Ophthalmology |
Therapeutic area mix
- Ophthalmology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Allergan · 1 shared drug class
- Andover Research Eye Institute · 1 shared drug class
- Aultman Health Foundation · 1 shared drug class
- Bausch & Lomb Incorporated · 1 shared drug class
- Bp Consulting, Inc · 1 shared drug class
- Chong Kun Dang Pharmaceutical · 1 shared drug class
- Clinica Oftamologica Zona Sul · 1 shared drug class
- AbbVie · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Fundação Altino Ventura:
- Fundação Altino Ventura pipeline updates — RSS
- Fundação Altino Ventura pipeline updates — Atom
- Fundação Altino Ventura pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Fundação Altino Ventura — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/funda-o-altino-ventura. Accessed 2026-05-18.